Plain-English translation of NCT06928519 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is comparing two different medication approaches for early-stage Parkinson's disease in patients in China. One group receives Madopar (levodopa/benserazide) alone, while the other receives Madopar combined with Entacapone. The study will track how well each treatment works over 24 weeks by measuring changes in motor symptoms, daily activities, and quality of life.
This medication combination may help people with Parkinson's get longer-lasting relief from their symptoms by preventing the body from breaking down the main Parkinson's drug too quickly. The trial aims to see if adding this second medication helps more than taking the first one alone.
You likely qualify if…
You likely don't qualify if…
You will take either Madopar alone or Madopar plus Entacapone exactly as your doctor prescribes—there are no study-assigned treatments. Over 24 weeks, you'll have visits where doctors will assess your motor symptoms, how well you're managing daily activities, and your overall quality of life. The study will also check your safety through blood tests, vital signs, and heart monitoring.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China